Envudeucitinib
A detailed overview of the drug Envudeucitinib
| Envudeucitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Envudeucitinib is a pharmaceutical drug that acts as a selective inhibitor of the enzyme tyrosine kinase 2 (TYK2). It is being developed for the treatment of various autoimmune diseases, including psoriasis and systemic lupus erythematosus.
Mechanism of Action[edit | edit source]
Envudeucitinib functions by selectively inhibiting the activity of TYK2, a member of the Janus kinase (JAK) family. TYK2 is involved in the signaling pathways of several cytokines that are critical in the pathogenesis of autoimmune diseases. By inhibiting TYK2, Envudeucitinib reduces the inflammatory response associated with these conditions.
Clinical Development[edit | edit source]
Envudeucitinib is currently undergoing clinical trials to evaluate its efficacy and safety in treating autoimmune diseases. The drug has shown promise in early-phase trials, demonstrating significant improvements in disease symptoms and markers of inflammation.
Potential Indications[edit | edit source]
Envudeucitinib is being investigated for use in several autoimmune conditions, including:
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Envudeucitinib includes its absorption, distribution, metabolism, and excretion. The drug is administered orally and has a bioavailability that allows for effective systemic distribution. It is metabolized primarily in the liver and excreted via the kidneys.
Safety and Side Effects[edit | edit source]
In clinical trials, Envudeucitinib has been generally well-tolerated. Common side effects include mild gastrointestinal disturbances and headache. Serious adverse effects are rare but may include increased risk of infections due to immunosuppression.
Research and Development[edit | edit source]
Ongoing research is focused on optimizing the dosing regimen of Envudeucitinib and expanding its potential therapeutic applications. Studies are also being conducted to better understand the long-term safety profile of the drug.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
